# Phase 1/2 pancreatic cancer trials recruiting: 90 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 90 trials in phase 1/2 for pancreatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 pancreatic cancer trials: 90 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/pancreatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 90
- Recruiting or not yet: 90
- Read on: November 19, 2026

## Trials

The 25 newest of 90, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07905131 | A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905131) |
| September 17, 2026 | NCT07824960 | Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma | University of Virginia | Phase 1/2 | Not yet recruiting | Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced... | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824960) |
| September 8, 2026 | NCT07806058 | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | Recruiting | Pancreatic Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806058) |
| September 3, 2026 | NCT07802184 | GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC | West China Hospital | Phase 1/2 | Recruiting | Metastatic Pancreatic Cancer | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802184) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| July 30, 2026 | NCT07736612 | A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer | Zhejiang University | Phase 1/2 | Not yet recruiting | Pancreatic Cancer, RAS Mutations or Amplifications | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736612) |
| July 14, 2026 | NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Theriva Biologics SL | Phase 1/2 | Recruiting | Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the Pancreas | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701486) |
| June 24, 2026 | NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer | University Health Network, Toronto | Phase 1/2 | Not yet recruiting | Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic, Pancreatic Adenocarcinoma Metastatic, Adenosquamous... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665684) |
| June 5, 2026 | NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | Blueprint Medicines Corporation | Phase 1/2 | Recruiting | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629960) |
| June 4, 2026 | NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627711) |
| June 2, 2026 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer... | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619521) |
| May 19, 2026 | NCT07595835 | CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Pancreatic Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595835) |
| May 19, 2026 | NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | West China Hospital | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595172) |
| May 19, 2026 | NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | Northwestern University | Phase 1/2 | Recruiting | Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594626) |
| May 4, 2026 | NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 | Orion Corporation, Orion Pharma | Phase 1/2 | Recruiting | Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer) | 229 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563738) |
| April 20, 2026 | NCT07539155 | Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer | University of Arkansas | Phase 1/2 | Recruiting | Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539155) |
| April 14, 2026 | NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | BigHat Biosciences, Inc. | Phase 1/2 | Recruiting | Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal... | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529808) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| March 31, 2026 | NCT07504263 | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies | Recurv Pharma Inc | Phase 1/2 | Not yet recruiting | Advanced Malignancies, Oncology, Colorectal Cancer, Pancreatic Cancer, Cancer | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07504263) |
| March 18, 2026 | NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480928) |
| March 17, 2026 | NCT07477418 | PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) | University of Vermont | Phase 1/2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477418) |
| March 3, 2026 | NCT07444541 | ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Anova Innovation Limited | Phase 1/2 | Recruiting | Pancreatic Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444541) |
| February 25, 2026 | NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | Sichuan Enray Pharmaceutical Sciences Company | Phase 1/2 | Recruiting | Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Vulva Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07433283) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| January 20, 2026 | NCT07353645 | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1/2 | Recruiting | Colorectal Cancer, Pancreatic Cancer | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07353645) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 3 |
| West China Hospital | 3 |
| National Cancer Institute (NCI) | 3 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 3 |
| Jacobio Pharmaceuticals Co., Ltd. | 2 |
| Fudan University | 2 |
| Essen Biotech | 2 |
| University of Virginia | 2 |
| Cancer Research UK | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| BigHat Biosciences, Inc. | 1 |
| [Shanghai JMT-Bio Inc.](https://specstream.ai/data/clinical-trials/company/shanghai-jmt-bio-inc) | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Engeneic Pty Limited | 1 |
| GI Innovation, Inc. | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| Filamon LTD | 1 |
| Shanghai Public Health Clinical Center | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| University Health Network, Toronto | 1 |
| MBrace Therapeutics | 1 |
| University Hospital Tuebingen | 1 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 1 |
| Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 1 |
| Fujian Provincial Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 39 |
| China | 31 |
| Spain | 10 |
| United Kingdom | 6 |
| Australia | 5 |
| Canada | 5 |
| South Korea | 4 |
| France | 3 |
| Netherlands | 3 |
| Germany | 3 |
| Puerto Rico | 2 |
| Italy | 2 |
| Denmark | 1 |
| Finland | 1 |
| Switzerland | 1 |
| Belgium | 1 |
| Ukraine | 1 |
| Ireland | 1 |
| Taiwan | 1 |
| Japan | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [IT consultants in the United States](https://specstream.ai/data/businesses/it-consultants/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
- [Cardiothoracic surgery practices in the United States](https://specstream.ai/data/businesses/cardiothoracic-surgery-practices/united-states)
- [Interior design firms in the United States](https://specstream.ai/data/businesses/interior-design-firms/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
- [Business consulting firms in the United States](https://specstream.ai/data/businesses/business-consulting-firms/united-states)
